Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 4/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.31 |
| ▸ | MGMT | P16455 | 4/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424170 | 0.75 | ABL1 (0.41) | CDK2 | |
| SCHEMBL3418435 | 0.74 | CCNA2 (0.35) | CCNA2CDK2CCNA1 | |
| SCHEMBL18084073 | 0.69 | CCNA2 (0.47) | CCNA2CDK2CCNA1PIK3CAALDH1A1 | |
| SCHEMBL2908497 | 0.66 | PIK3CA (0.37) | CCNA2CDK2CCNA1MPOCDK1 | |
| SCHEMBL16828162 | 0.64 | CCNA2 (0.50) | CCNA2CDK2CCNA1PIK3CAALDH1A1 | |
| SCHEMBL4104572 | 0.63 | CCNA2 (0.41) | CCNA2CDK2CCNA1PIK3CAKDM4E | |
| SCHEMBL5484380 | 0.63 | PNP (0.44) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL10617813 | 0.62 | CCNA2 (0.48) | CCNA2CDK2CCNA1PIK3CAKDM4E | |
| Hydrochloric Acid SCHEMBL16828222 | 0.62 | CCNA2 (0.48) | CCNA2CDK2CCNA1PIK3CAALDH1A1 | |
| SCHEMBL30721418 | 0.62 | CCNA2 (0.48) | CCNA2CDK2CCNA1PIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| EP-1995330-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1427743-A4 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6962991-B2 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20040191824-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-1427743-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | Epoch Biosciences, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003022859-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | CCNA2 2019/4885CDK2 553/4885CCNA1 2383/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | CCNA2 4870/4885CDK2 4077/4885CCNA1 4881/4885 |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | CCNA2 2019/4885CDK2 553/4885CCNA1 2383/4885 |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | CCNA2 2019/4885CDK2 553/4885CCNA1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.